New drug trial aims to ease fragile x symptoms in men

NCT ID NCT07654114

Recruiting now Symptom relief Sponsor: Connecta Therapeutics, S.L. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called CTH120 in 30 adult men with Fragile X syndrome. The main goal is to see if the drug is safe and tolerable, while also checking if it helps improve symptoms. Participants will receive the drug and be monitored closely for side effects and changes in their condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FRAGILE X SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system disorder Congenital Abnormalities fragile X syndrome intellectual disability Neurobehavioral Manifestations Rare Diseases X-linked disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAGILE X SYNDROME FRAGILE X SYNDROME (FXS)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Consorci Corporació Sanitaria Parc Taulí. Institut Investigació i Innovació Parc Taulí (I3PT)
RECRUITING

Sabadell, Barcelona, 08208, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••
Hospital del Mar Medical Research Institute
RECRUITING

Barcelona, Barcelona, 08003, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••